Popular terms

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Cholesterol patents



      

This page is updated frequently with new Cholesterol-related patent applications.




Date/App# patent app List of recent Cholesterol-related patents
04/07/16
20160096898 
 Pc33718e patent thumbnailPc33718e
The present invention provides antagonizing antibodies, antigen-binding portions thereof, and aptamers that bind to proprotein convertase subtilisin kexin type 9 (pcsk9). Also provided are antibodies directed to peptides, in which the antibodies bind to pcsk9.
Rinat Neuroscience Corp.


04/07/16
20160095889 
 Composition and use of lactobacillus reuteri gmnl-263 in decreasing blood lipid levels patent thumbnailComposition and use of lactobacillus reuteri gmnl-263 in decreasing blood lipid levels
A use of a lactobacillus reuteri gmnl-263 in decreasing blood lipid levels is disclosed. Lactobacillus reuteri gmnl-263 (accession no.: cctcc m 209263) specifically inhibits gene expression related to pro-inflammatory factor and lipid synthesis and promotes gene expression related to cholesterol metabolism.
Genmont Biotech Inc.


04/07/16
20160095888 
 Methods of using krill oil to treat risk factors for cardiovascular, metabolic, and inflammatory disorders patent thumbnailMethods of using krill oil to treat risk factors for cardiovascular, metabolic, and inflammatory disorders
This invention discloses methods of using krill oil and compositions comprising krill oil to treat risk factors for metabolic, cardiovascular, and inflammatory disorders. The present invention also relates to methods of using compositions comprising krill oil to modulate biological processes selected from the group consisting of glucose metabolism, lipid biosynthesis, fatty acid metabolism, cholesterol biosynthesis, and the mitochondria respiratory chain.
Aker Biomarine Antarctic As


04/07/16
20160095835 
 Compositions containing omega-3 oil and uses thereof patent thumbnailCompositions containing omega-3 oil and uses thereof
The invention provides pharmaceutical compositions containing omega-3 oil and a non-hydrophilic co-solvent that have an increased absorption rate. The pharmaceutical compositions may further contain one or more pharmaceutical organic molecules.
Maine Natural Health Company, Inc.


03/31/16
20160089355 
 Composition for preventing the occurrence of cardiovascular event in multiple risk patient patent thumbnailComposition for preventing the occurrence of cardiovascular event in multiple risk patient
Disclosed is a composition which is useful for preventing the occurrence of a cardiovascular event, particularly a composition which is expected to show a prophylactic effect on a cardiovascular event occurring in a hypercholesterolemia patient despite providing the patient with a treatment with hmg-coa ri or a cardiovascular event occurring in a multiple risk patient.. .
Mochida Pharmaceutical Co., Ltd.


03/24/16
20160084858 
 Systems and methods for non-fasting ldl cholesterol assays patent thumbnailSystems and methods for non-fasting ldl cholesterol assays
In one embodiment, a test strip for testing for cholesterol-related blood analytes in whole blood includes a red blood cell separation layer, the red blood cell separation layer separating red blood cells from a blood sample applied to the test strip as the blood sample flows downward through the red blood cell separation layer. The test strip further includes a reaction layer receiving the blood sample from the red blood cell separation layer, the reaction layer including poe-pop-poe block copolymer, a surfactant, and a reflectivity changing reactant, the poe-pop-poe block copolymers solubilizing essentially only non-ldl cholesterol analytes, the non-ldl cholesterol analytes reacting with the reflectivity changing reactant in order to change a reflectivity of the blood sample..
Polymer Technology Systems, Inc.


03/24/16
20160083425 
 Proprotein convertase subtilisin kexin type 9 (pcsk9) allosteric binding ligands to modulate serum low density lipoprotein (ldl) levels patent thumbnailProprotein convertase subtilisin kexin type 9 (pcsk9) allosteric binding ligands to modulate serum low density lipoprotein (ldl) levels
This invention is related to the field of hypercholesterolemia. In particular, the invention provides compositions and methods to modulate circulating levels of low density lipoproteins by altering the conformation of the protein pcsk9 using synthetic ligands and/or synthetic ligand derivative sequences of 3-8 amino acids ranging between 350-2,000 da.
Srx Cardio, Llc


03/24/16
20160082061 
 Nutritional composition and  manufacture patent thumbnailNutritional composition and manufacture
A nutritional composition, and method of making it, that includes a carbohydrate, an insulin potentiator, an amino acid, a muscle growth stimulator, an energy increaser, at least one natural supplement for weight loss, reduction of cholesterol levels, and/or increased resistance to stress, and at least one flavoring ingredient. The composition may be provided in dry form for addition to a fluid or in liquid forms.

03/24/16
20160081994 
 Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects patent thumbnailMethods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects
The present invention provides methods and compositions for treating hyperlipidemia and/or hypercholesterolemia comprising administering to the subject an effective amount of an mtp inhibitor to inhibit hyperlipidemia and/or hypercholesterolemia in said subject, wherein said administration comprises an escalating series of doses of the mtp inhibitor. In some embodiments the method comprises administering at least three step-wise, increasing dosages of the mtp inhibitor to the subject.
The Trustees Of The University Of Pennsylvania


03/24/16
20160081385 
 Process patent thumbnailProcess
A method for reducing the amount of cholesterol and/or improving the texture and/or reducing weight loss and/or increasing the fat stability of a meat based food product comprising: a) contacting meat with a lipid acyltransferase; b) incubating the meat contacted with the lipid acyltransferase at a temperature between about 1° c. To about 70° c.; c) producing a food product from the meat; wherein step b) is conducted before, during or after step c).
Dupont Nutrition Biosciences Aps


03/17/16
20160074473 

Effect of phospholipid composition of reconstituted hdl on its cholesterol efflux and anti-inflammatory properties


The present invention relates to peptide-phospholipid formulations, methods of generating these formulations and methods of administering these formulations for treatment. The present disclosure also provides methods for increasing cholesterol efflux, inducing anti-atherosclerotic activity, increasing pre-β hdl, inducing anti-inflammatory activity, inhibiting cytokine release (including cytokines tnf-α, il-1β, and/or il-6 or a combination thereof) and increasing cholesterol mobilization and/or esterification by administering the peptide-phospholipid formulations disclosed..
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv


03/17/16
20160074419 

Preparation and uses of obeticholic acid


Or a pharmaceutically acceptable salt, solvate or amino acid conjugate thereof. Obeticholic acid is useful for the treatment or prevention of a fxr mediated disease or condition, cardiovascular disease or cholestatic liver disease, and for reducing hdl cholesterol, for lowering triglycerides in a mammal, or for inhibition of fibrosis.

03/17/16
20160074417 

Sr-bi as a predictor of human female infertility and responsiveness to treatment


Methods of diagnosis and treatment of diseases and disorders related to de novo synthesis of cholesterol, based on allelic variants of the scavenger receptor class b type i receptor, and kits for use therein.. .
The Johns Hopkins University


03/17/16
20160074384 

Extending and maintaining micropore viability of microneedle treated skin with lipid biosynthesis inhibitors for sustained drug delivery


Microneedles and their use as a physical skin permeation enhancement technique facilitate drug delivery across the skin in therapeutically relevant concentrations. Micropores created in the skin by mns reseal because of normal healing processes of the skin, thus limiting the duration of the drug delivery window.
University Of Kentucky Research Foundation


03/17/16
20160074363 

Methods for improving lipid profiles using atrasentan


The present disclosure is directed to methods for reducing cardiovascular risk in a human subject by administering atrasentan, or a pharmaceutically acceptable salt thereof, in an amount sufficient to effect a reduction of about 5% or more in one or both of (a) total serum cholesterol, relative to the subject's baseline total serum cholesterol, and (b) serum ldl cholesterol, relative to the subject's baseline serum ldl cholesterol.. .
Abbvie Inc.


03/10/16
20160068812 

Method for culturing skeletal muscle for tissue engineering


The invention provides a nutrient medium composition and associated methods for lengthening the useful life of a culture of muscle cells. Disclosed is a method of culturing mammalian muscle cells, including preparing one or more carriers coated with a covalently bonded monolayer of trimethoxy-silylpropyl-diethylenetriamine (deta); verifying deta monolayer formation by one or more associated optical parameters; suspending isolated fetal rat skeletal muscle cells in serum-free medium according to medium composition 1; plating the suspended cells onto the prepared carriers at a predetermined density; leaving the carriers undisturbed for cells to adhere to the deta monolayer; covering the carriers with a mixture of medium 1 and medium 2; and incubating.
University Of Central Florida Research Foundation, Inc.


03/10/16
20160067243 

Ketoconazole enantiomer in humans


Treatment of patients with the 2s,4r ketoconazole enantiomer or its pharmaceutically acceptable salts, and solvates is useful for reducing systemic inflammation and cholesterol levels and improving glycemic control.. .
Cortendo Ab (publ)


03/03/16
20160058768 

Substituted amide compounds


The present invention is directed at substituted amide compounds, pharmaceutical compositions containing such compounds and the use of such compounds to reduce plasma lipid levels, such as ldl-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by high levels of ldl-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases, in mammals, including humans.. .
Pfizer Inc.


02/25/16
20160054305 

Method for measuring bile salt export transport and/or formation activity


A method is provided to measure modulation of bile salt export transport and/or formation activity in hepatocyte or stable cell line preparations by test agents including but not limited to drugs, drug candidates, biologicals, food components, herb or plant components, proteins, peptides, dna, rna. Furthermore, the method is to determine modulation of bile salt export transport and/or formation activity not only by said test agents, but further their metabolites or biotransformed products formed in situ.
Biotranex, Llc


02/18/16
20160046633 

Bmp inhibitors and methods of use thereof


The present invention provides small molecule inhibitors of bmp signaling. These compounds may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with bmp signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation.
The U.s.a., As Represented By The Secretary, Department Of Health & Human Services


02/18/16
20160046575 

Novel forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, gamma-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1)


Novel forms of [r—(r*,r*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid hemi calcium salt designated form xx, form xxi, form xxii, form xxiii, form xxiv, form xxv, form xxvi, form xxvii, form xxviii, form xxix, and form xxx, characterized by their x-ray powder diffraction, solid-state nmr, and/or raman spectroscopy are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, benign prostatic hyperplasia (bph) and alzheimer's disease.. .
Warner-lambert Company Llc


02/18/16
20160045595 

Nanoparticles, composed of sterol and saponin from quillaja saponaria molina process for preparation and use thereof as carrier for amphipatic of hydrophobic molecules in fields of medicine including cancer treatment and food related compounds


A nanoparticle comprising at least one sterol, e.g. cholesterol and a component from quillaja saponaria molina (quilq) selected from quillaja saponin, characterized in that said nanoparticles do not comprise a phospholipid and in that the sterol molecule is bound by a hydrophobic bond between a hydroxyl group of the sterol and terpene moieties in a quil a micelle and by an hydrophilic ester bond between a sterol oh− and cooh− or aldehyde groups in the quila micelle.
Moreinx Ab


02/11/16
20160039945 

Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9


The present invention provides compositions and methods relating to or derived from antigen binding proteins capable of inhibiting pcsk9 binding to ldlr. In embodiments, the antigen binding proteins specifically bind pcsk9.
Amgen Inc.


02/11/16
20160039804 

Novel oxazolidinone derivative as cetp inhibitor, its preparation method, and pharmaceutical composition comprising the same


Disclosed are a novel oxazolidinone derivative exhibiting inhibitory activity against cetp, a preparation method thereof, and a pharmaceutical composition comprising the same. Exhibiting excellent inhibitory activity against cetp, the oxazolidinone derivative can be effectively applied to the prevention or treatment of various cetp enzyme activity- or hdl cholesterol level-related diseases such as dyslipidemia, atherosclerosis, and coronary heart disease..
Dong-a St Co., Ltd.


02/11/16
20160038554 

Composition for reducing blood lipid and use thereof as healthcare dietary supplements


The present invention discloses a blood lipid-reducing composition, the active components of the composition are composed of fish oil, linseed oil, phytosterol ester or phytosterol. The composition mainly comprises components such as a-linolenic acid, epa, dha and phytosterol or phytosterol ester, can reduce serum total cholesterol (tc), triglyceride (tg) and low-density lipoprotein cholesterol (ldl-c), has an efficacy of reducing blood lipid.
Infinitus (china) Company Ltd.


02/04/16
20160032014 

Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9


The present invention provides compositions and methods relating to or derived from antigen binding proteins capable of inhibiting pcsk9 binding to ldlr and having increased ph sensitivity, improved binding affinity and/or increased in vivos half life. In embodiments, the antigen binding proteins specifically bind pcsk9 and have increased ph sensitivity, improved binding affinity and/or increased in vivos half life.
Amgen Inc.


02/04/16
20160031951 

Peptides having reduced toxicity that stimulate cholesterol efflux


The present invention provides a family of non-naturally occurring polypeptides having cholesterol efflux activity that parallels that of full-length apolipoproteins (e.g., apo ai and apo e), and having high selectivity for abca1 that parallels that of full-length apolipoproteins. Further, the peptides of the invention have little or no toxicity when administered at therapeutic and higher doses.
The Regents Of The University Of California


02/04/16
20160031935 

Small molecule modulators of pcsk9 and methods of use thereof


A compound of formula (i): or a pharmaceutically acceptable salt, hydrate, solvate, or racemic mixture or stereoisomer thereof, and methods for preventing or treating an ldl-cholesterol-related disease or disorder using such compound(s), and kits and compositions comprising such compound(s).. .
Amorchem Holdings Inc.


02/04/16
20160030562 

Methods to enhance cancer treatment


Herein are provided methods for reducing or eliminating cancer in a patient in need of cancer treatment, by providing cholesterol deprivation therapy (cdt) in conjunction with antibodies directed against cholesterol-deprived tumor cells. Further provided are methods of enhancing the efficacy of other cancer treatments, by administering cdt and antibodies directed against cholesterol-deprived tumor cells, in combination with additional anti-cancer therapies..
International Business Machines Corporation


01/28/16
20160024554 

Rapid, low-sample-volume cholesterol and triglyceride assays


Reagents, assays, methods, kits, devices, and systems for rapid measurement of cholesterol and cholesterol sub-fractions from a blood sample are provided. Total cholesterol, low density lipoprotein cholesterol, and high density lipoprotein cholesterol can be measured in a single assay using kinetic measurements, under conditions in which cholesterol sub-species are converted to a detectable product at distinct rates.
Theranos, Inc.


01/28/16
20160024173 

Non-hemolytic llo fusion proteins and methods of utilizing same


The present invention provides recombinant proteins or peptides comprising a mutated listeriolysin o (llo) protein or fragment thereof, comprising a substitution or internal deletion of the cholesterol-binding domain or a portion thereof, fusion proteins or peptides comprising same, nucleotide molecules encoding same, and vaccine vectors comprising or encoding same. The present invention also provides methods of utilizing recombinant proteins, peptides, nucleotide molecules, and vaccine vectors of the present invention to induce an immune response to a peptide of interest..
Advaxis, Inc.


01/28/16
20160024063 

Novel 3-(4(benzyloxy)phenyl)hex-4-inoic acid derivative, preparing same and pharmaceutical composition for preventing and treating metabolic disease including same as effective ingredient


The present invention relates to a novel 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative, a preparation method thereof, and a pharmaceutical composition comprising the same as an active ingredient for the prevention and treatment of metabolic disease. The novel 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative, the optical isomer thereof, or the pharmaceutically acceptable salt thereof of the present invention has excellent activities of activating gpr40 protein and promoting insulin secretion accordingly but has no toxicity when co-administered with other drugs.
Hyundai Pharm Co., Ltd


01/28/16
20160022768 

Reconstituted high density lipoprotein formulation and production method thereof


A reconstituted high density lipoprotein formulation having relatively low toxicity comprises an apolipoprotein such as apoai or fragment thereof, a lipid and a detergent at a level which is about 5-50% of that which would normally cause liver toxicity upon administration to a human. The lipid is optimally phosphatidylcholine at about 30-50 g/l and the molar ratio of apolipoprotein:lipid is optimally in the range 1:40 to 1:75.
Csl Limited


01/28/16
20160022701 

Neuroactive steroids, compositions, and uses thereof


Provided are methods of evaluating or treating a patient, e.g., a patient having a disorder described herein, comprising: a) optionally, acquiring a patient sample; b) acquiring an evaluation of and/or evaluating the sample for an alteration in the level s24(s)-hydroxycholesterol compared to a reference standard.. .
Sage Therapeutics, Inc.


01/21/16
20160015775 

Lipopeptides for use in treating liver diseases and cardiovascular diseases


The present invention relates to lipopeptide-based compounds for use in the diagnosis, prevention and/or treatment of a liver disease or condition, preferably liver involved metabolic diseases, as well as in the control or modification of the cholesterol level or cholesterol uptake and, thus, diagnosis, prevention and/or treatment of a cardiovascular disease. The present invention furthermore relates to an in vitro or in vivo assay or method for testing or measuring the ntcp-mediated transport of test compound(s).
Ruprecht-karls-universitÄt Heidelberg


01/21/16
20160015673 

Method for lowering cholesterol


The present invention relates to the diagnosis, risk assessment, prevention, and treatment of senile dementia of the alzheimer's type (sdat). More specifically the present invention relates to the measurement of ethanolamine phospholipids in human serum.
Phenomenome Discoveries Inc.


01/21/16
20160015050 

Vegetable oil composition containing palm mid-fraction fat and reducing plasma cholesterol


A method and composition for reducing the cholesterolemic effect in mammals of ingesting a blended nutritional fat composition containing a palm mid-fraction (pmf) hardstock fat combined with an unsaturated vegetable oil. The composition is solid or semi-solid at 20° c.
Brandeis University


01/14/16
20160010088 

Method for inhibiting tumor growth through rna-interference using liposomally associated cdc20 sirna


Liposomal compositions comprising of liposomes of guanidinylated cationic amphiphiles as the main lipid and cholesterol/1,2-dioleoyl-sn-glycero-3-phosphocholine (dopc)/aminopropyl polyethyleneglycol carbamyl-distearoylphosphatidyl-ethanolamine (dspe-peg-nh2) as co-lipids are described. These liposomal compositions containing encapsulated or electrostatically complexed therapeutic small interfering rnas (sirnas) against cdc20, a key cell cycle regulator, inhibit solid tumor growth and melanoma tumor growth on lung in c57bl/6j mice..
Council Of Scientific & Industrial Research


01/14/16
20160009748 

Plasminogen activator inhibitor-1 inhibitors and methods of use thereof to modulate lipid metabolism


The invention relates to plasminogen activator-1 (pai-1) inhibitor compounds and uses thereof in the treatment of any disease or condition associated with elevated pai-1. The invention includes, but is not limited to, the use of such compounds to modulate lipid metabolism and treat conditions associated with elevated pai-1, cholesterol, or lipid levels..
Eastern Michigan University


01/14/16
20160008300 

Compositions and methods for nutritional supplementation


Some embodiments herein are directed to a nutritional supplement composition including effective amounts of coenzyme q10, fish oil, vitamin d and a pharmaceutically acceptable excipient. Some embodiments describe a method of promoting nutritional health comprising administering a nutritional supplement composition including coenzyme q10, fish oil, vitamin d and a pharmaceutically acceptable excipient to a subject in need thereof.

01/07/16
20160002255 

Antidiabetic bicyclic compounds


Novel compounds of the structural formula (i), and the pharmaceutically acceptable salts thereof, are agonists of g-protein coupled receptor 40 (gpr40) and may be useful in the treatment, prevention and suppression of diseases mediated by the g-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia..
Merck Sharp & Dohme Corp.


01/07/16
20160002224 

Novel indole derivatives useful as anti-diabetic agents


Novel compounds of the structural formula (i) are activators of amp-protein kinase and may be useful in the treatment, prevention and suppression of diseases mediated by the ampk-activated protein kinase. The compounds of the present invention may be useful in the treatment of type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension..
Merck Sharp & Dohme Corp.


12/31/15
20150377913 

Device and determination of an analyte in blood


A sample acquiring device, an apparatus and a method for spectrophotometric measurement of high density lipoprotein (hdl) and at least one of total cholesterol (tc), triglycerides (tg) and glucose (fpg).. .
Hemocue Ab


12/31/15
20150377902 

Serological methods and diagnostic tests for syphilis antibodies


A method of detecting antibodies to syphilis antigens includes providing a syphilis detection kit having a screening solid-phase platform with a screening portion coated with non-treponemal syphilis antigens. The screening portion is fabricated by initially dissolving cholesterol in an organic solvent and further diluting the dissolved cholesterol in an ethanol solution comprising cardiolipin and lecithin to form an antigen solution, permitting the antigen solution to evaporate at the screening portion and at least partially coating the screening portion with an antigen coating, and stabilizing the antigen coating into a syphilis antigen complex by overcoating the antigen coating with an overcoat solution comprising an inert protein..
Awareness Technology Inc.


12/31/15
20150376139 

Anti-pcsk9 compounds and methods for the treatment and/or prevention of cardiovascular diseases


Disclosed are compounds that modulate the physiological action of the proprotein convertase subtilisin kexin type 9 (pcsk9), and methods of using these modulators to reduce ldl-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease (cvd), including treatment of hypercholesterolemia.. .
Shifa Biomedical Corporation


12/31/15
20150376123 

Biguanide derivative, preparation method thereof, and pharmaceutical composition containing same as an active ingredient


A biguanide derivative compound with n4-n5 substitution, which is represented by formula 1, or a pharmaceutically acceptable salt thereof, a method of preparing the same, and a pharmaceutical composition containing the same as an active ingredient are provided. The biguanide derivative may exhibit excellent effect on activation of ampk and inhibition of cancer cell proliferation in a low dose, compared with conventional drugs, and thus, may be useful to treat diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, fatty liver, coronary artery disease, osteoporosis, polycystic ovarian syndrome, metabolic syndrome, cancer, etc..
Hanall Biopharma Co., Ltd.


12/31/15
20150374783 

Products and methods using soy peptides to lower total and ldl cholesterol levels


Controlled studies demonstrate that products and related methods using soy related peptides lower total and ldl cholesterol levels in individuals. In one exemplary embodiment of the present disclosure, a product containing an effective amount of lunasin peptides that lowers cholesterol levels in an individual that consumes the lunasin peptides is provided.
Soy Labs, Llc


12/31/15
20150374710 

Anti-proprotein convertase subtilisin kexin type 9 (anti-pcsk9) compounds and methods of using the same in the treatemnt and/or prevention of cardiovascular diseases


Disclosed are compounds that modulate the physiological action of the proprotein convertase subtilisin kexin type 9 (pcsk9), as well as therapeutic methods for use of such compounds to reduce ldl-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease (cvd), including treatment of hypercholesterolemia. Examples of compounds include thiadiazole, isoxazole, 1,2,4-triazole, thiazole, indole, pyrazole, and pyrrolinone derivatives..
Shifa Biomedical Corporation


12/24/15
20150368641 

Methods to screen compounds for regulating usf1 activity and methods and compounds to treat cardiometabolic and lipid pathologies


The deficiency of usf1 confers a remarkable number of clinically relevant beneficial metabolic effects in mice via activation of brown adipose tissue. The usf1 deficient mice have high serum hdl-cholesterol and low triglyceride levels, a beneficial lipid profile opposite to that of human metabolic syndrome.
Terveyden Ja Hyvinvoinnin Laitos (thl)


12/24/15
20150366824 

Induction of estrogen receptor beta by cholesterol biosynthesis inhibitors and methods of treatment of cancer


Disclosed herein are methods and compositions related to the discovery that cholesterol inhibitors induce the anti-proliferative protein, estrogen receptor beta (erβ), in both erα-positive and erα-negative breast cancer cell lines, including triple negative cells.. .
The Curators Of The University Of Missouri


12/17/15
20150361434 

Novel low molecular weight cyclic amine containing cationic lipids for oligonucleotide delivery


The instant invention provides for novel cationic lipids that can be used in combination with other lipid components such as cholesterol and peg-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that demonstrates enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver.
Sirna Therapeutics, Inc.


12/17/15
20150359824 

Improved omega-3 food supplement based on marine oil


A food supplement omega 3 based on marine oils (extracted from fish, fish byproducts, mollusks, krill, algae, microalgae) to fight against hypercholesterolemia and lipoprotein disruption leading to atherosclerosis and so to cardiovascular diseases. Optimization of lipid prevention score (lps) of at least one food supplement omega 3 by adding either high or low lps oil (vegetable and/or marine) according to the lps of the omega 3 based marine oils.

12/10/15
20150353980 

Preparation of 7-dehydrocholesterol and/or the biosynthetic intermediates and/or secondary products thereof in transgenic organisms


The present invention relates to a method for preparing 7-dehydrocholesterol and/or the biosynthetic intermediates and/or secondary products thereof by culturing organisms, in particular yeasts. Furthermore, the invention relates to the preparation of the nucleic acid constructs required for preparing the genetically modified organisms and to said genetically modified organisms, in particular yeasts, themselves..
Organobalance Gmbh


12/10/15
20150352139 

Combination of anticholesterolemic fiber


The present invention relates to fiber compositions comprising fiber derived from onion and soluble fiber. Additionally, the invention relates to food products comprising said fiber compositions.
Universitat De Lleida


12/03/15
20150344540 

Novel glp-1 receptor agonists with cholesterol efflux activity


The present invention provides novel glucagon-like protein-1 (glp-1) receptor agonist compounds that promote cholesterol efflux. The abca1-mediated cholesterol efflux present invention also provides compositions comprising the novel glucagon-like protein-1(glp-1) receptor agonist compounds, and relates to the use of said compounds in therapy, to methods of treatment comprising administration of said compounds to patients, and to the use of said compounds in the manufacture of medicaments..
Novo Nordisk A/s


12/03/15
20150344455 

Compounds, compositions and methods useful for cholesterol mobilization


The invention relates to classes of pharmaceutically-active heterocyclic compounds and pharmaceutically acceptable salts, and hydrates thereof, and compositions comprising the same. The invention also relates to methods for treating or preventing a disease or disorder, which comprises administering a therapeutically or prophylactically effective amount a compound described herein..
Cerenis Therapeutics Holding Sa


12/03/15
20150344430 

Methods of lowering proprotein convertase subtilisin/kexin type 9 (pcsk9)


The invention relates to new methods of modulating cholesterol by inhibiting proprotein convertase subtilisin/kexin type 9 (pcsk9) with fatty acid derivatives; and new methods for treating or preventing a metabolic disease comprising the administration of an effective amount of a fatty acid derivative. The present invention is also directed to fatty acid bioative derivatives and their use in the treatment of metabolic diseases..
Catabasis Pharmacauticals, Iinc.


12/03/15
20150344389 

Cycloalkyl-hydroxyl compounds and compositions for cholesterol management and related uses


The present invention relates to novel cycloalkyl-hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, alzheimer's disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, syndrome x, thrombotic disorder. Compounds and methods of the invention can also be used to modulate c reactive protein or enhance bile production in a patient.
Esperion Therapeutics, Inc.


12/03/15
20150344388 

Hydroxyl compounds and compositions for cholesterol management and related uses


The present invention relates to novel hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, alzheimer's disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, pancreatitius, parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, metabolic syndrome disorders (e.g., syndrome x), thrombotic disorder. Compounds and methods of the invention can also be used to modulate c reactive protein or enhance bile production in a patient.
Esperion Therapeutics, Inc.


12/03/15
20150342931 

Spirocyclic cetp inhibitors


Compounds having the structure of formula (i), including pharmaceutically acceptable salts of the compounds, are cetp inhibitors and may be useful for raising hdl-cholesterol and reducing ldl-cholesterol in human patients and for treating or preventing atherosclerosis. The chemical compounds that are disclosed cholesterol ester transfer protein (cetp) and are expected to have utility in raising hdl-c, lowering ldl-c, and in the treatment and prevention of atherosclerosis..
Merck Sharp & Dohme Corp.


12/03/15
20150342240 

Nutritional walnut-based compositions


A high nutrition food spread providing walnut-based compositions are disclosed. The spreads have desirable taste and consistency characteristics as well as palatability.

11/26/15
20150337362 

Method for the specific isolation of nucleic acids of interest


A method and diagnostic kit for selective isolation of microorganisms of interest and/or nucleic acids of interest including: a) bringing a liquid biological sample into contact with a saponin formulation to destabilize untargeted elements within the liquid biological sample, b) inducing osmotic shock of the untargeted elements to specifically lyse the untargeted elements, c) adding a solution of at least one enzyme capable of lysing free nucleic acids derived from the untargeted elements lysed in solution in the sample, and d) selectively obtaining the microorganisms of interest or the nucleic acids of interest. A precipitant of the unlysed microorganisms of interest may be optionally added in solution.
Biomerieux


11/26/15
20150336884 

Novel synthetic antioxidants and their uses


The present invention relates to synthetic organic antioxidants of small molecules. The novel dithiol-containing compounds in this invention possess strongest possible capability as both scavenger for free radicals and antioxidant.

11/26/15
20150335615 

Cholesterol-lowering compounds in combination with lipid metabolism-altering compounds of non-absorbable sugars, compounds that convert nh3 to nh4+, or hydrogen-generating compounds for the treatment of high cholesterol and inflammation


A composition for treating high cholesterol, including synergistically effective amounts of a cholesterol-lowering agent and a lipid metabolism-altering compound chosen from a non-absorbable sugar, a compound that converts nh3 to nh4+, a hydrogen-generating compound, and combinations thereof. A composition for treating high cholesterol, including synergistically effective amounts of a statin chosen from atorvastatin, cerivastatin, fluvastain, lovastatin, mevastatin, pitavastatin, pravastatin, rosuvastatin, and simvastatin, and lactulose.

11/19/15
20150328276 

Medical formulation for treating hypercholesterolemia


The present invention relates to a medical formulation comprising: cinnamomum zeylanicum; pinus pinaster; extract of a plant belonging to the saccharum genus; monascus purpureus; taraxacum officinale; camellia sinensis; vitamin b3; alpha tocopherol; coenzyme q10; fish oil comprising eicosapentaenoic acid and docosahexanoic acid; beta-glucan; and/or cholecalciferol. The invention also relates to the medical formulation as a medicament, and especially for treating hypercholesterolemia..

11/19/15
20150328184 

Compositions and methods for glycemic control of subjects with impaired fasting glucose


Compositions and methods for providing anti-diabetic and anti-hyperlipidemia benefits to diabetic subjects currently on medication but not meeting recommended targets for blood glucose, hba1c, blood pressure and total cholesterol.. .
Kgk Synergize, Inc.


11/19/15
20150328142 

Sublingual administration of statins


The invention provides a pharmaceutical composition for the transmucosal delivery of a statin, said composition comprising a statin and a carrier in which said statin is soluble or forms a suspension or emulsion. The invention also provides a pharmaceutical composition comprising a statin for use in inhibiting cholesterol synthesis in vivo, where in said use said composition is delivered by the transmucosal route..
Londonpharma Ltd.


11/12/15
20150322627 

Process for refining chemicals from pulp and paper mill wastewaters


A process for isolating at least one target compound, such as manool, geranyl linalool, ethyl guaiacol, eugenol, veratraldehyde, squalene, terpin, cholesterol, beta-sitosterol, campesterol, stigmasterol, stigmastenol and dehydroabietic acid, from biomass, the process including steps of: obtaining a condensate from a recovery evaporator, a reverse osmosis retentate of a condensate of a pulp and paper mill, or both, the condensate, retentate or both being substantially free of higher molecular weight (approximately >1000 da) cellulose and/or lignin and/or lignin-derived material; optionally ph adjusting and filtering the condensate to collect insoluble material; extracting the condensate, the collected insoluble material, or both, with solid phase extraction (spe), liquid-liquid extraction or solid-liquid extraction to produce an extract containing the at least one target compound; and optionally purifying the extract containing the at least one target compound by thermal fractionation, chromatographic separation, recrystallization ion exchange, chelation, adsorption/desorption, lyophilization and sublimation or combinations thereof. The method is particularly useful for isolating the target compounds from wastewaters produced in a kraft pulp and paper mill, especially from recovery evaporator condensates produced during the treatment of black liquor..
Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Environment


11/12/15
20150322032 

Statins of omega-3 polyunsaturated acids for treating hypercholesterolemia


The present invention relates to novel statin derivatives of omega-3 fatty acids, and their use in treating hypercholesterolemia, obesity, hypertriglyceridemia, cardiovascular diseases, and metabolic diseases, and alzheimer's disease.. .
Jiva Pharma, Inc.


11/12/15
20150322023 

Biaryl- or heterocyclic biaryl-substituted cyclohexene derivative compounds as cetp inhibitors


The present invention provides biaryl- or heterocyclic biaryl-substituted cyclohexene derivative compounds, isomers thereof, or pharmaceutically acceptable salts. The compounds of the invention show a cetp inhibitory effect that increases hdl-cholesterol levels and reduces ldl-cholesterol levels.
Chong Kun Dang Pharmaceutical Corp.


11/12/15
20150320769 

Sulfated-oxysterol and oxysterol sulfation by hydroxysterol sulfotransferase promote lipid homeostasis and liver proliferation


Methods and compositions for the prevention and treatment of liver damage or disease in a subject in need thereof are provided. The methods involve providing the sulfated oxysterol 25-hydroxycholesterol-3-sulfate (25hc3s) to the subject e.g.
Virginia Commonwealth University


11/12/15
20150320724 

Methods of treating diabetes by administering a glucagon receptor antagonist in combination with a cholesterol absorption inhibitor


Use of a glucagon receptor antagonist in combination with a cholesterol absorption inhibitor for the treatment of diabetes and related conditions is disclosed.. .
Merck Sharp & Dohme Corp.


11/12/15
20150320064 

Creamy yogurt base


This creamy yogurt base provides a base with similar appearance, texture, and taste to cream cheese and sour cream products, but contains less calories, fat, and cholesterol while providing a similar mouth feel associated with consuming these full fat products. Additionally, this product can replace common fats used in cooking, baking, and frozen systems.

11/05/15
20150315621 

One-pot fermentation process for simvastatin production


Simvastatin is a drug used in treatment of hypercholesterolemia because of its inhibitory activities towards cholesterol biosynthesis. The technology described herein is a novel method of biosynthesizing simvastatin directly from an engineered microbial host (such as saccharomyces cerevisiae) using an engineered biosynthetic pathway.
The Regents Of The University Of California


11/05/15
20150315584 

Compositions and methods for silencing apolipoprotein c-iii expression


The present invention provides compositions comprising therapeutic nucleic acids such as interfering rna that target apolipoprotein c-iii (apoc3) gene expression, lipid particles comprising one or more (e.g., a cocktail) of the therapeutic nucleic acids, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles (e.g., for the treatment of lipid diseases or disorders such as atherosclerosis or a dyslipidemia such as hypertriglyceridemia or hypercholesterolemia).. .
Protiva Biotherapeutics, Inc.


11/05/15
20150315178 

Plasminogen activator inhibitor-1 inhibitors and methods of use thereof


The invention relates to plasminogen activator-1 (pai-1) inhibitor compounds and uses thereof in the treatment of any disease or disorder associated with elevated pai-1. The invention includes, but is not limited to, the use of such compounds to prevent or reduce thrombosis and fibrosis, to promote thrombolysis, and to modulate lipid metabolism and treat diseases or disorders associated with elevated pai-1, cholesterol, or lipid levels..
Eastern Michigan University


11/05/15
20150315112 

Novel low molecular weight cationic lipids for oligonucleotide delivery


The instant invention provides for novel cationic lipids that can be used in combination with other lipid components such as cholesterol and peg-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that demonstrates enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver.
Sirna Therapeutics, Inc.






Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Cholesterol for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Cholesterol with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.7124

5204

1 - 1 - 104